

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-24. (Cancelled)

25. (Currently Amended) An isolated antibody or antigen-binding fragment thereof which specifically binds to ~~an amino acid sequence of SEQ ID NO: 5~~ in a polypeptide comprising 20 or more contiguous amino acids of SEQ ID NO: 5, wherein the specific binding is to the SEQ ID NO: 5 portion of the polypeptide.

26. (Previously presented) An isolated antibody or antigen-binding fragment thereof which specifically binds to a polypeptide consisting of the amino acid sequence of SEQ ID NO: 5.

27-35. (Cancelled)

36. (Previously presented) The antibody or fragment of claim 25 which is a monoclonal antibody.

37. (Previously presented) The antibody or fragment of claim 25 which is a polyclonal antibody, an anti-idiotypic antibody, a chimeric antibody, a Fab fragment, a F(ab)₂ fragment or a labeled antibody.

38. (Previously presented) The antibody or fragment of claim 26 which is a monoclonal antibody.

39. (Previously presented) The antibody or fragment of claim 26 which is a polyclonal antibody, an anti-idiotypic antibody, a chimeric antibody, a Fab fragment, a F(ab)₂ fragment or a labeled antibody.

40-41. (Cancelled)

42. (Previously presented) The antibody or fragment of claim 25 complexed with said polypeptide.

43. (Previously presented) The antibody or fragment of claim 26 complexed with said polypeptide.

44-47. (Cancelled)

48. (Previously presented) A composition comprising the antibody or fragment of claim 25 and a pharmaceutically acceptable carrier.

49. (Previously presented) The composition of claim 48 wherein the antibody or fragment is a monoclonal antibody.

50. (Previously presented) A composition comprising the antibody or fragment of claim 26 and a pharmaceutically acceptable carrier.

51. (Previously presented) The composition of claim 50 wherein the antibody or fragment is a monoclonal antibody.

52-53. (Cancelled)

54. (Previously presented) The antibody or fragment of claim 25 which is bound to a solid support.

55. (Previously presented) The antibody or fragment of claim 26 which is bound to a solid support.

56-57. (Cancelled)

58. (Previously presented) The antibody or fragment of claim 54 bound to said polypeptide.

59. (Previously presented) The antibody or fragment of claim 55 bound to said polypeptide.

60-62. (Cancelled)

63. (Previously presented) A recombinant antibody which binds specifically to a polypeptide consisting of the amino acid sequence of SEQ ID NO: 5.

64. (Previously presented) A composition comprising the antibody of claim 63 and a pharmaceutically acceptable carrier.

65. (Previously presented) The composition of claim 48 consisting essentially of said antibody or fragment and a pharmaceutically acceptable carrier.

66. (Previously presented) The composition of claim 49 consisting essentially of said monoclonal antibody and a pharmaceutically acceptable carrier.

67. (Previously presented) The composition of claim 50 consisting essentially of said antibody or fragment and a pharmaceutically acceptable carrier.

68. (Previously presented) The composition of claim 51 consisting essentially of said monoclonal antibody and a pharmaceutically acceptable carrier.

69. (Previously presented) The composition of claim 64 consisting essentially of said recombinant antibody and a pharmaceutically acceptable carrier.

70. (Previously presented) The composition of claim 48 consisting of said antibody or fragment and a pharmaceutically acceptable carrier.

71. (Previously presented) The composition of claim 49 consisting of said monoclonal antibody and a pharmaceutically acceptable carrier.

72. (Previously presented) The composition of claim 50 consisting of said antibody or fragment and a pharmaceutically acceptable carrier.

73. (Previously presented) The composition of claim 51 consisting of said monoclonal antibody and a pharmaceutically acceptable carrier.

74. (Previously presented) The composition of claim 64 consisting of said recombinant antibody and a pharmaceutically acceptable carrier.